Heterozygous COL4A3 Variants in Histologically Diagnosed Focal Segmental Glomerulosclerosis by Braunisch, Matthias C. et al.
ORIGINAL RESEARCH
published: 12 June 2018
doi: 10.3389/fped.2018.00171
Frontiers in Pediatrics | www.frontiersin.org 1 June 2018 | Volume 6 | Article 171
Edited by:
Max Christoph Liebau,
Klinik und Poliklinik für Kinder- und
Jugendmedizin, Universitätsklinikum
Köln, Germany
Reviewed by:
Rizaldy Paz Scott,
Division of Nephrology &
Hypertension, Feinberg School of
Medicine, Northwestern University,
United States
Rachel Lennon,
University of Manchester,
United Kingdom
*Correspondence:
Julia Hoefele
julia.hoefele@tum.de
Specialty section:
This article was submitted to
Pediatric Nephrology,
a section of the journal
Frontiers in Pediatrics
Received: 25 March 2018
Accepted: 24 May 2018
Published: 12 June 2018
Citation:
Braunisch MC, Büttner-Herold M,
Günthner R, Satanovskij R,
Riedhammer KM, Herr PM, Klein HG,
Wahl D, Küchle C, Renders L,
Heemann U, Schmaderer C and
Hoefele J (2018) Heterozygous
COL4A3 Variants in Histologically
Diagnosed Focal Segmental
Glomerulosclerosis.
Front. Pediatr. 6:171.
doi: 10.3389/fped.2018.00171
Heterozygous COL4A3 Variants in
Histologically Diagnosed Focal
Segmental Glomerulosclerosis
Matthias C. Braunisch 1,2, Maike Büttner-Herold 3, Roman Günthner 1,2,
Robin Satanovskij 1,2, Korbinian M. Riedhammer 1,2, Pierre-Maurice Herr 2,
Hanns-Georg Klein 4, Dagmar Wahl 4, Claudius Küchle 1, Lutz Renders 1, Uwe Heemann 1,
Christoph Schmaderer 1 and Julia Hoefele 2*
1Department of Nephrology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, 2 Institute of Human
Genetics, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, 3Department of Nephropathology,
Institute of Pathology, Friedrich-Alexander-University, Erlangen, Germany, 4Center for Human Genetics and Laboratory
Diagnostics Dr. Klein, Dr. Rost and Colleagues, Martinsried, Germany
Introduction: Steroid-resistant nephrotic syndrome (SRNS) is one of the most frequent
causes for chronic kidney disease in childhood. In ∼30% of these cases a genetic
cause can be identified. The histological finding in SRNS is often focal segmental
glomerulosclerosis (FSGS). In rare cases, however, pathogenic variants in genes
associated with Alport syndrome can be identified in patients with the histological finding
of FSGS.
Materials and Methods: Clinical information was collected out of clinical reports and
medical history. Focusedmolecular genetic analysis included sequencing ofCOL4A5 and
COL4A3 in the index patient. Segregation analysis of identified variants was performed
in the parents and children of the index patient.
Results: The female index patient developed mild proteinuria and microscopic
hematuria in childhood (12 years of age). The histological examination of the kidney
biopsies performed at the age of 21, 28, and 32 years showed findings partly compatible
with FSGS. However, immunosuppressive treatment of the index patient did not lead to
a sufficient reduction of in part nephrotic-range proteinuria. After the patient developed
hearing impairment at the age of 34 years and her daughter was diagnosed with
microscopic hematuria at the age of 6 years, re-examination of the index’s kidney biopsies
by electron microscopy revealed textural changes of glomerular basement membrane
compatible with Alport syndrome. Molecular genetic analysis identified two missense
variants in COL4A3 in a compound heterozygous state with maternal and paternal
inheritance. One of them is a novel variant that was also found in the 6 year old daughter
of the index patient who presented with microscopic hematuria.
Discussion: We were able to show that a novel variant combined with a previously
described variant in compound heterozygous state resulted in a phenotype that was
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histologically associated with FSGS.Molecular genetic analysis therefore can be essential
to solve difficult cases that show an unusual appearance and therefore improve
diagnostic accuracy. Additionally, unnecessary and inefficient treatment with multiple side
effects can be avoided.
Keywords: Alport syndrome, COL4A3, focal segmental glomerulosclerosis, FSGS, nephrotic syndrome, hearing
impairment
INTRODUCTION
Steroid-resistant nephrotic syndrome (SRNS) is one of the most
frequent causes for chronic kidney disease especially in young
adulthood (1, 2). In around 30% of cases amonogenetic cause can
be identified (3). Histological findings in SRNS largely present
as focal segmental glomerulosclerosis (FSGS) with progressive
glomerular scarring (4). To date, more than 30 genes associated
with SRNS have been identified placing the podocyte into the
center of attention regarding the pathogenesis of SRNS and FSGS
(5). Immunosuppressive treatment of proteinuria in hereditary
FSGS often cannot induce remission and is also poorly tolerated
(6, 7).
In rare cases, FSGS can be caused by variants in COL4A3
and COL4A4, both genes associated with Alport syndrome
(AS) (8). AS typically occurs with the leading symptoms
of progressive renal failure, sometimes associated with the
extrarenal manifestations of hearing impairment (sensorineural
deafness) and/or ocular abnormalities (anterior lenticonus,
cataract) (9). In AS the first sign is microscopic hematuria in early
childhood. Proteinuria increases as disease progresses. However,
proteinuria commonly does not reach nephrotic range in contrast
to FSGS or SRNS (10).
Variants in COL4A5 are the most frequent causes involved
in the pathogenesis of AS and account for about 85% of cases
(9). Due to the X-linked inheritance of COL4A5 mostly men are
affected. In fewer cases, variants in COL4A3 and COL4A4 located
at the long arm of chromosome 2 account for an autosomal
recessive (14% of cases) or autosomal dominant (1% of cases) AS
(11, 12). Male and female patients are equally affected.
Due to mainly economic reasons, genetic testing is often
reluctantly used in clinical routine. Molecular genetic diagnosis
can improve accuracy of disease classification, especially in
phenotypes with multiple symptoms and unusual appearance
and help to create personalized treatment options.
Here we report one novel COL4A3 variant in a compound
heterozygous state in a 34 year old woman with hematuria and
proteinuria who presented initially with histological findings
compatible with FSGS. Only after hearing impairment occurred
later in life, genetic testing of AS associated genes was initiated
and the correct diagnosis was made.
Abbreviations: ACE, angiotensin-converting enzyme; AS, Alport syndrome;
ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; GBM,
glomerular basement membrane; MMF, mycophenolate mofetil; NC1, C-terminal
globular non-collagenous domain; SRNS, steroid-resistant nephrotic syndrome;
TBMN, thin basement membrane nephropathy.
MATERIALS AND METHODS
Clinical Case Information
The study was approved by the local Ethics Committee of
the Technical University of Munich and performed according
to the standard of the Helsinki Declaration of 1975. Written
informed consent was obtained from the index patient and their
relatives for publication. Clinical and phenotype information was
gathered out of clinical reports and medical history.
Histology
Histological examinations of the kidney biopsies at the age
of 28 and 32 years were performed with light microscopy of
sections stained with Periodic acid-Schiff (PAS) reaction and
hematoxylin and eosin staining, immunohistochemistry and
electron microscopy. Immunohistochemistry of the latest biopsy
was performed with antibodies specific for IgA, IgG, IgM, C1q,
and C3c (all polyclonal rabbit antibodies, Dako; Dilution and
Code No. IgA 1:200000, A0262, IgG 1:150000, A0423, IgM
1:100000, A0425, C1q 1:100000, A0136, C3c 1:100000, A0062)
after digestion with PronaseE for 45min. For detection Envision
Kit (Dako) was applied and DAB was used as a chromogen.
For electron microscopy fixed renal biopsies were dehydrated
and embedded in Epon. Semithin and ultrathin sections were
prepared and stained with methylene blue or uranyl acetate/lead
citrate, respectively. Ultrathin sections were then analyzed with a
Zeiss electron microscope LEO EM 910 or LEO EM 912 (Zeiss,
Oberkochen, Germany) at various magnifications. Histological
and electron microscopic images were only available from the
latest kidney biopsy.
Genetics
Blood samples were collected after written informed consent.
Genomic DNA was extracted from peripheral blood of the
index patient, her parents, and her children using the Gentra
Puregene Blood Kit (Qiagen, Hilden, Germany) according to
manufacturer’s instructions. In the index patient exon 1 to
51 of COL4A5 were examined followed by exon 1 to 52
of COL4A3 using direct DNA sequencing on both strands
applying the dideoxy chain termination method on an ABI
capillary sequencer 3730 (Applied Biosystems, Foster City, USA).
Primers were designed by Primer3 program (http://frodo.wi.mit.
edu/primer3/input.htm). For segregation analysis, subsequent
targeted sequencing was performed in both parents and children
of the index patient in exon 26 and 52 of the COL4A3 gene.
DNA alignment and sequence variant analysis were carried out
using the Sequence PilotCE software (JSIMedical SystemsGmbH,
Kippenheim, Germany) and compared to EMBL (European
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Molecular Biology Laboratory) and GenBank databases as well
as our in-house database. All variants were validated in a second
independent DNA sample. Scaled gene structure was created with
the Gene Structure Display Server version 2.0 (13).
RESULTS
Clinical Phenotype
Index Patient
A 34 year old Caucasian woman of German ancestry presented
in our department (Figure 1A, II-2). At the age of 12 years,
mild proteinuria and microscopic hematuria was detected. This
finding was, however, not followed.
At the age of 21 years, the index patient had, for the first-time,
increased proteinuria (>1 g per day) and mild hypertension. The
histology of a kidney biopsy showed, besides minimal mesangial
cell proliferation, uncharacteristic findings. Therefore, no specific
therapy was initiated. Unfortunately, no detailed report of the
first kidney biopsy was available.
In the presence of persistent proteinuria of >1 g/d and a
decrease of creatinine clearance from 83 to 65 mL/min/1.73
m2 re-biopsy of the kidney was performed at the age of 28
years. The diagnosis at that time was chronic kidney disease
due to FSGS with secondary hypertension and proteinuria. The
clinical presentation was normal, besides a slightly increased
weight (body mass index 24.7 kg/m2) possibly due to the
discrete lower leg edema. Especially, there was no report of
hearing impairment. Further laboratory work-up is shown
in Table 1. Ultrasound examination showed morphologically
normal kidneys. The histology of the kidney biopsy revealed focal
global glomerulosclerosis with mild chronic tubulo-interstitial
damage. Electron microscopy showed one scarred glomerulus
and one glomerulus with clumsy podocyte foot processes with
effacement compatible with the diagnosis of primary FSGS. Due
to a gross proteinuria and the progressive decline of kidney
function an angiotensin-converting enzyme (ACE) inhibitor and
immunosuppressive therapy with cyclosporine for 7 months and
prednisolone were initiated.
Four years later, at the age of 32 years, the patient experienced
nephrotic range proteinuria (4.5 g per day). In the beginning,
the patient responded well to immunosuppressive treatment
with prednisolone (starting dose 60mg, tapered to 7.5mg once
daily) and mycophenolate mofetil (MMF) (250mg twice daily)
with a reduction of the proteinuria to 1.7 g per day. To further
reduce the proteinuria,MMFwas increased to 500mg twice daily.
Nonetheless, proteinuria increased again to 4.3 g/d. Therefore,
MMF was discontinued and the patient was admitted to our
hospital for a kidney biopsy. Clinical presentation at that time
was age-appropriate, besides discrete lower leg edema. Abnormal
laboratory values are shown in Table 1.
Light microscopy of the third kidney biopsy revealed
renal parenchyma with 11 glomeruli of which four were
obliterated (Figure 2A). In one obliterated glomerulus fibrous
thickening of the Bowman’s capsule was present, indicating
fibrous synechia (Figure 2C). Crescents were not identified.
The remaining glomeruli were unremarkable (Figure 2D). No
segmental sclerosis, extra- or intracapillary proliferation was
seen. Patchy tubular atrophy and interstitial fibrosis was
present in ∼15% (Figures 2E,F) and was accompanied by
a mild lymphoplasmacytic interstitial infiltrate. Additionally,
multiple foam cell nests were present in the interstitium
(Figure 2B). Arterial vessel walls showed mild thickening
(Figure 2G) and moderate arteriolar hyalinosis (Figure 2H). In
immunohistochemical stainings with antisera against IgA, IgG,
IgM, C1q, and C3c only mild mesangial staining for IgM was
seen (Figure 3). Furthermore, electron microscopy showed that
the GBM (glomerular basement membrane) was moderately
thinned with extensive foot process effacement and microvillous
transformation of podocytes going in line with the former report
of primary FSGS (Figure 4). After an in-patient stay, an increase
of MMF to 750 mg/d was recommended. Hypertension and
proteinuria were treated with an ACE inhibitor and candesartan.
Two years later, at the age of 34 years, the patient developed
moderate inner ear hearing impairment. Additionally, the 6 year
old daughter of the index patient was diagnosed withmicroscopic
hematuria. This new clinical symptomatology combined with a
conspicuous family history led to a re-examination of electron
microscopy of the kidney biopsy performed at the age of
32 years. In further electron microscopic analyses, segments
with thinning and thickening of the GBM (170–700 nm) were
found. Moreover, changes in the texture of the GBM were
seen in some segments with mild lamellation and basket-woven
texture. Moderate effacement of the foot processes was present
(Figure 4). The re-evaluation of the ultra-thin sections revealed
the beforehand described podocyte abnormalities in addition
to structural changes of the GBM. Therefore, the changes in
GBM structure in the context of the clinical findings and
family history were suspicious of hereditary kidney disease and
prompted a molecular genetic examination of genes involved in
the pathogenesis of AS.
Relatives
The daughter of the index patient presented with microscopic
hematuria at the age of 6 years as alreadymentioned above. So far,
the son of the index patient does not show any clinical symptoms
of a kidney disease at the age of 9 years. Neither the mother nor
the father of the index patient developed (chronic) kidney disease
until the age of 54 and 58 years, respectively.
Genetic Analysis
Pathogenic variants in COL4A5 could not be identified. The
sequencing of COL4A3 (NM_000091.4) revealed two missense
variants in a compound heterozygous state in the index patient:
c.1892G>T, p.Gly631Val (paternally inherited) and c.4981C>T,
p.Arg1661Cys (maternally inherited) (Figure 1A, I-1 and I-
2). The variants are located in exon 26 and 52, respectively
(Figures 1B,D). Each parent is a heterozygous carrier for one
variant (Figure 1B). The amino acid at position 631 is highly
conserved in evolution (Figure 1C). It is located in the triple
helical collagenous domain of the type IV collagen alpha-3 chain
(Figure 1D). The variant has not been described in the literature
before. The second variant, p.Arg1661Cys, has been described
previously and is mostly associated to early development of
end-stage renal disease (ESRD) (8, 12, 14). The encoded amino
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FIGURE 1 | Pedigree of the family, conservations and location of identified variants. (A) Pedigree of the family; solid symbols, affected individuals; circles, females;
squares, males; yrs, years. (B) Partial nucleotide sequence of exon 26 and 52 of COL4A3 of the patient, her parents and her children. (C) Conservation of the affected
amino acid over five different species; A, Alanine; C, Cysteine; G, Glycine; I, Isoleucine; P, Proline; Q, Glutamine; R, Arginine; S, Serine; T, Threonine; V, Valine. (D)
Exon-intron structure of COL4A3 (NM_000091.4) with the localization of the two identified variants. The variant p.Gly631Val lies in the central triple helical domain,
whereas the variant p.Arg1661Cys lies in the C-terminal cysteine-rich non-collagenous domain (NC1) which is together with the 7S domain at the N-terminal a
cross-linking domain. bp, base pairs; CDS, coding sequence; kb, kilo base pairs; UTR, untranslated region.
acid is located in the cross-linking C-terminal globular non-
collagenous domain (NC1) (14) (Figure 1D). The daughter of the
index patient carries the newly discovered variant p.Gly631Val
(Figure 1A, III-2). This variant was also present in the father of
the index patient (Figure 1A, I-1). The son of the index patient
carries the variant p.Arg1661Cys (Figure 1A, III-1).
DISCUSSION
We identified a novel variant in COL4A3 combined with a
previously described variant in a compound heterozygous state.
In the context of the progressive proteinuria and the young age of
the index patient the initial diagnosis was erroneously considered
to be hereditary FSGS as it was the most probable differential
diagnosis. The present study highlights the importance of
including AS in the differential diagnosis of FSGS, especially
when disease onset is early in life (<25 years of age). In these
cases, it would be helpful to start a molecular genetic analysis
promptly (i.e., already if mild proteinuria is present).
Several reports have linked variants in COL4A3 and COL4A4
to patients with nephrotic-range proteinuria and the histological
findings of FSGS (8, 15).
In these cases, FSGS most likely occurs secondary to
GBM pathology and therefore represents an independent entity
different from primary FSGS with podocytopathy. Histologic
diagnosis of FSGS depends on the size of the kidney biopsy as
FSGS due to its local nature is prone to sampling error.
Using molecular diagnostics, we identified a novel missense
variant in COL4A3. The variant p.Gly631Val is assumed
to be disease-causing as it segregates within the family
and since glycine is important for the spatial organization
of the collagen triple helix as it resides at every third
position of the collagen type IV chain. Using PolyPhen-
2 (http://genetics.bwh.harvard.edu/pph/) and MutationTaster
(http://www.mutationtaster.org) to predict possible functional
effects, the variant was classified as probably damaging
(PolyPhen-2) and disease-causing (MutationTaster). The variant
was not found in our in-house database and in the genome
Aggregation Database (gnomAD).
The daughter of the index patient, who is a heterozygous
carrier of the variant, already demonstrated microscopic
hematuria in early childhood (6 years of age). This can be a
first sign of thin basement membrane nephropathy (TBMN).
However, the father of the index patient, who also carried this
variant, showed no signs of (chronic) kidney disease going in line
with the wide range of clinical phenotypes reported in individuals
with single heterozygous variants (8, 12, 16).
The second variant, p.Arg1661Cys, has been identified both
in a heterozygous and compound-heterozygous state in patients
with autosomal recessive AS mostly at an early age at diagnosis
of 10–18 years (in one case 44 years of age). In one case ESRD
was reached at 19 years of age (8, 12). Previous cases presented
with nephrotic range proteinuria (2–5 g/d), thickened GBM
and foot process effacement. Hearing loss was reported in one
of six cases. No ocular disease was reported (8, 12). However,
so far, the variant was only reported in heterozygous form to
be associated with ESRD (8) (family DUK6585, individual 1).
Elsewhere, the variant was reported in a compound-heterozygous
state, however, age of renal failure was not indicated (12).
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FIGURE 2 | Light microscopy of the kidney biopsy. (A) Renal biopsy performed at the age of 32 years with patchy tubular atrophy and interstitial fibrosis (upper left;
magnification x100). (B) Multiple interstitial foam cell nests (asterisk) and an obliterated glomerulus (upper left; magnification x400), which shows in (C) residues of
fibrous synechia (arrow; magnification x400). (D) One unremarkable glomerulus (magnification x400). (E,F) Interstitial fibrosis and tubular atrophy with mild
lymphoplasmacytic interstitial infiltrate (arrows) (E; magnification x200; F; magnification x400). (G) Arterial vessel walls showed mild thickening (arrow) and moderate
arteriolar hyalinosis (H). All images were taken from sections stained with Periodic acid-Schiff (PAS) reaction.
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TABLE 1 | Abnormal blood and urine laboratory values.
Reference range Values
28 years of age 32 years of age
BLOOD
Blood urea nitrogen 7–18 md/dL 19.6 39
Creatinine 0.5–1.1 mg/dL 1.2 1.1–1.4
Phosphate 2.5–4.5 mg/dL – 4.7
GFR (MDRD) >60 mL/min/1.73 m2 – >60
Uric acid 3–7 mg/dL 8.1 –
Total serum protein 6.0–8.0 g/dL 5.6 5.7
Lactate dehydrogenase <244 U/L 284 353–433
Anti-nuclear antibodies <1: 120 1:120 –
SERUM ELECTROPHORESIS
Alpha-1 1.5–4.0% 4.2 –
Alpha-2 5.0–9.0% 11.5 –
ß-globulin 7.0–12.0% 12.9 –
URINE
Proteinuria <150 mg/g creatinine 1465 316
Albuminuria <20 mg/g creatinine 1384 –
Alpha-1-microglobulinuria <14 mg/g creatinine 14.1 –
Leukocyturia 0–3 per visual field – 4–10
Erythrocyturia 0–3 per visual field - 4–10
GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
FIGURE 3 | Immunohistochemistry of the kidney biopsy. Immunohistochemistry stainings (magnification x400) with antisera against IgA (A), IgG (B), IgM with mild
mesangial staining (C, arrow), C1q (D), and C3c (E) showed only mild background staining at the endothelial aspect of the capillary loops without deposits suspicious
of immune-complex glomerulonephritis.
This exemplifies the wide range of clinical manifestation of
heterozygous variants reaching from familial benign hematuria
to AS with development of ESRD. The healthy son and the
mother of the index patient carry the same variant and did not
develop (chronic) kidney disease so far.
Because both parents and children of the index patient carry
a heterozygous variant they should be monitored closely by a
(pediatric) nephrologist if hypertension, proteinuria, or renal
impairment is present (17). In this case, an ACE inhibitor therapy
should be evaluated. Otherwise, in the absence of these symptoms
regular examination every 1–2 years should be performed by
a primary care physician (17). In patients with TBMN and
isolated microscopic hematuria chronic renal failure is rare
(16). However, if TBMN is accompanied by proteinuria, it
has been associated with an increased risk to late onset FSGS
with nephrotic syndrome (18, 19). Furthermore, in clinically
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FIGURE 4 | Electron microscopy of the kidney biopsy. (A) In the ultrastructural
analysis performed at the age of 32, podocytes showed strong foot process
effacement with microvillous transformation and thinned glomerular basement
membrane (GBM) with mild lamellation (white arrow) compatible with the
preexisting diagnosis of primary FSGS (magnification x10,000). In additional
ultrastructural analyses performed at the age of 34, segments with thinning
and thickening of the GBM (B; magnification x16,000) with disrupted
basket-woven texture (C, asterisk; magnification x16,000) were found. en,
endothelium; po, podocyte; fp, foot process; fp eff, podocyte food process
effacement.
affected patients with heterozygous variants inCOL4A3, COL4A4
an increased risk of progression to chronic renal failure was
observed in up to 38% and a progression to ESRD was observed
in up to 20% (15). Age of ESRD onset was significantly earlier
in untreated patients with heterozygous variants in COL4A3,
COL4A4, and COL4A5 compared to those treated with blockade
of the renin aldosterone system (20). Patients that progress to
chronic renal failure and ESRD could have variants in hitherto
unknown modifier genes.
The rapid course of disease in one family (DUK6696) with
compound heterozygous variants in COL4A3 (p.Glu131fs∗151
and p.Gln936∗) and nephrotic range proteinuria and hematuria
with ESRD at 8 to 12 years of age described by Malone et al.
is comparable to our family (8). However, the severity and the
more rapid course to ESRD in the previous report could be
explained by the presence of two loss of function variants whereas
our index patient has compound heterozygous missense variants.
This is in line with a genotype-phenotype correlation postulated
for COL4A3 as nonsense or larger rearrangement variants lead to
a shortening of the protein and are associated with a younger age
at renal failure (<20 years) (15, 21). The unusual appearance of
AS with nephrotic range proteinuria in our index patient and the
cases described by Malone et al. could be additionally modified
by variants in FSGS genes that alter the podocyte in collagen
IV-related kidney disease and therefore, could explain the high
clinical variability. However, Malone et al. was not able to identify
variants in genes associated with FSGS in his cohort (8).
Our index patient developed hearing impairment at the age
of 34 years. In general, hearing loss seems to occur more often
in cases with variants in COL4A3 as compared to COL4A4
(8, 12), but is not mandatory. In the study of Malone et al.,
hearing impairment was only diagnosed in all 8 of 15 individuals
with variants in COL4A3 after genetic testing had already been
done (8). Accordingly, in our case otologic examination was not
performed at earlier age probably due to the absence of (severe)
symptoms.
Several points may have led to the misdiagnosis of hereditary
FSGS in our index patient. First, the quality of the kidney biopsy
was low. The histological definition of FSGS comprises a broad
spectrum of different pathologies together. So far it is not possible
to definitely differentiate between subgroups of FSGS based on
the morphology. To improve diagnostic accuracy ultrastructural
analysis including measurements of the GBM in ultra-thin slices
could be helpful to identify GBM defects. In most cases genetic
testing has no therapeutic consequence except for the omission of
immunosuppressive therapy and therefore avoidance of adverse
side effects. Next generation sequencing would allow a much
faster and more accurate diagnosis in clinically and genetically
heterogeneous cases. Second, nephrotic proteinuria is unusual for
AS (10). Third, classical AS symptoms (e.g., hearing impairment)
occurred late in the medical history. Fourth, variants in COL4A3
show a highly variable clinical phenotype. Fifth, as classically men
are affected by X-linked inherited AS female patients may be
overseen.
Genetic implications are different for patients with autosomal
recessive AS and could highlight caution in case of a kidney
transplantation. The mode of inheritance is different compared
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to X-linked AS. A heterozygous (autosomal dominant)
affection with microscopic hematuria and TBMN warrants
a restrained selection as kidney donor. This is especially
important if blood pressure is high or proteinuria is present
(17). Therefore, the newly discovered p.Gly631Val variant
with the clinical presentation of microscopic hematuria
in the daughter indicates caution for selection as kidney
donor.
In patients with AS and TBMN ACE inhibitors are
recommended by the expert guidelines for the treatment
of hypertension and proteinuria especially in individuals
with genetic variants (17). Angiotensin-receptor blockers
and aldosterone inhibitors could show additional effects
on the reduction of proteinuria (22). To date, new insights
for the treatment of AS are expected from the EARLY
PRO-TECT Alport trail that is evaluating the effect of
renin-angiotensin blockade on proteinuria and renal failure
progression (23).
Some limitations of the present study have to be stated. We
performed only targeted sequencing of COL4A3 and COL4A5 as
this study was already performed several years ago. Examination
of disease modifiers for collagen IV that could explain the high
variability of phenotypes described before were not performed
(8). Today panel diagnostics, whole exome or whole genome
sequencing would be done in such a case. Also, we did not
examine other genes or modifiers related to FSGS, which should
be included in further studies to improve the understanding
of the high variability of the clinical phenotype. Due to
the absence of cryopreserved tissue of the kidney biopsies,
it was not possible to perform immunofluorescence analysis
with antibodies specific for alpha-3,4,5 subunits of collagen IV
complex in the GBM and therefore directly document collagen
dysfunction. Unfortunately, electron microscopic images for a
re-examination were only available from the last kidney biopsy.
CONCLUSION
We were able to show that a novel variant combined with
a previously described variant in COL4A3 in compound
heterozygous state can lead to a phenotype that was erroneously
associated with hereditary FSGS. Finally, our study exemplifies
the importance of molecular examination in the diagnosis of
the renal phenotype to improve diagnostic accuracy and avoid
unnecessary inefficient treatment with immunosuppression.
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